RE:PwC sees continuation of US$ 5 to 15 Billion Bio M&A DealsAs the market moves into H2 '22 PwC's Potter wrote in a recent report highlighting the broad appeal of M&A action in health care. "The continuation of the $5 billion to $15 billion biotech deals, combined with medium-sized pharma ($50 billion) and medical device ($25 billion) deals is expected to drive significant investment dollars in M&A."